Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ku Qin Formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by the Yueyang Hospital of Integrative Medicine at the Shanghai University of Traditional Chinese Medicine. It is primarily investigated for the treatment of prurigo nodularis, a chronic inflammatory skin condition characterized by symmetric, intensely pruritic nodules. The formula's name is derived from its two primary constituent herbs: Ku Shen (Sophora flavescens) and Huang Qin (Scutellaria baicalensis), which are traditionally used in TCM to clear heat and dry dampness. In clinical research, the formula is being evaluated as a sequential or adjunctive therapy alongside the IL-4/IL-13 inhibitor dupilumab. The study aims to determine if the addition of Ku Qin Formula can accelerate itch relief, improve skin lesion clearance, and potentially allow for a shorter duration of dupilumab treatment while maintaining long-term disease control and safety.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ku Qin Formula.